Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AOC3 | Q16853 | 5/20 | 0.57 |
| ▸ | MIF | P14174 | 1/20 | 0.51 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.50 |
| ▸ | MAOA | P21397 | 3/20 | 0.46 |
| ▸ | MAOB | P27338 | 3/20 | 0.46 |
| ▸ | HRH3 | Q9Y5N1 | 5/20 | 0.45 |
| ▸ | BCAT2 | O15382 | 1/20 | 0.43 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.43 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.43 |
| ▸ | PRKCI | P41743 | 1/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16827426 | 0.82 | BCAT2 (0.46) | AOC3MAOAMAOBHRH3BCAT2 | |
| SCHEMBL22725954 | 0.82 | AOC3 (0.55) | AOC3MIFMAOAMAOBBCAT2 | |
| SCHEMBL29438665 | 0.82 | BCAT2 (0.46) | AOC3MAOAMAOBHRH3BCAT2 | |
| SCHEMBL22713726 | 0.82 | CYP11B1 (0.53) | AOC3MIFMAOAMAOBBCAT2 | |
| SCHEMBL22725923 | 0.81 | AOC3 (0.62) | AOC3LRRK2MAOAMAOBHRH3 | |
| SCHEMBL14158182 | 0.80 | BCAT2 (0.53) | AOC3MAOAMAOBBCAT2CYP11B1 | |
| SCHEMBL25304979 | 0.80 | CYP11B2 (0.54) | AOC3MAOAMAOBHRH3BCAT2 | |
| SCHEMBL29438664 | 0.80 | CYP11B2 (0.54) | AOC3MAOAMAOBHRH3BCAT2 | |
| SCHEMBL12955566 | 0.77 | CYP11B1 (0.46) | AOC3LRRK2MAOAMAOBBCAT2 | |
| SCHEMBL4301131 | 0.76 | LMNA (0.47) | AOC3MAOAMAOBBCAT2CYP11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11396495-B2 | Amine compound for inhibiting SSAO/VAP-1 and use thereof | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2022-07-26 | — | — | US | disclosed |
| US-11396495-B2 | Amine compound for inhibiting SSAO/VAP-1 and use thereof | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2022-07-26 | — | — | US | disclosed |
| US-20200377461-A1 | AMINE COMPOUND FOR INHIBITING SSAO / VAP-1 AND USE THEREOF | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2020-12-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11396495-B2 | Amine compound for inhibiting SSAO/VAP-1 and use thereof | VCAM1, VAPB, ICAM1 | AOC3 6/4885MIF 931/4885LRRK2 563/4885 |
| US-20200377461-A1 | AMINE COMPOUND FOR INHIBITING SSAO / VAP-1 AND USE THEREOF | VCAM1, VAPB, ICAM1 | AOC3 6/4885MIF 931/4885LRRK2 563/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.